Annovis Bio Prices $15 Million Public Offering to Fund Alzheimer's and Parkinson's Drug Development

Annovis Bio Inc. (NYSE: ANVS) announced the pricing of an underwritten public offering of 7,895,000 shares of common stock and accompanying warrants to purchase up to 7,105,500 additional shares, at a combined offering price of $1.90 per share and warrant. The company expects gross proceeds of approximately $15 million before expenses, with net proceeds intended to support continued clinical development of buntanetap for Alzheimer’s and Parkinson’s disease, as well as working capital and general corporate purposes.

This capital raise comes as Annovis Bio advances its lead drug candidate, buntanetap (formerly posiphen), through Phase 3 clinical trials. Buntanetap is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. By addressing the underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients.

The offering is significant for the company as it seeks to fund costly late-stage trials. Alzheimer's disease affects millions worldwide, and current treatments offer only symptomatic relief. Buntanetap's unique mechanism targeting multiple toxic proteins could potentially modify disease progression, representing a substantial unmet medical need. Similarly, Parkinson's disease impacts over 10 million people globally, and there is a critical need for therapies that slow or stop neurodegeneration.

Proceeds from the offering will be crucial for Annovis to complete its ongoing Phase 3 studies and potentially bring buntanetap to regulatory submission. The company's focus on neurodegenerative diseases places it at the forefront of a competitive but vital therapeutic area. Successful development of buntanetap could provide a first-in-class treatment option for patients.

The offering is underwritten, indicating institutional confidence in the company's prospects. However, the dilutive nature of the stock issuance may concern existing shareholders. The warrants attached to the offering could lead to further dilution if exercised. Nonetheless, the immediate need for capital to advance clinical trials often outweighs dilution concerns for biotech firms at this stage.

For more details on the offering, visit https://ibn.fm/KRpCW. Additional information about Annovis Bio and its pipeline can be found at www.annovisbio.com. Follow the company on LinkedIn, YouTube, and X for updates.